1-7 of 7
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CEAddressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Amy Mottl, MD, MPH
Muthiah Vaduganathan, MD, MPH
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
CME/CEADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
Reshma L. Mahtani, DO
Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
CME/CE Broadcast ReplayPulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
Vallerie V. McLaughlin, MD
Marsha Burks, BSN, RN
Rajan Saggar, MD
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
CME/CEEnhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
Carlos M. de Castro, MD
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CEChairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Jorge E. Cortes, MD
Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment
CME/CEExpert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment
Michael J. Mauro, MD
- advertisement
Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
CME/CEExpert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
Mark Socinski, MD
Patrick Forde, M.B.B.Ch.
Karen Reckamp, MS, MD
